Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy

Activating mutations in FLT3 confer poor prognosis for individuals with acute myeloid leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered by acquired resistance and myelosuppression attributed to a ‘synthetic lethal to...

Descripción completa

Detalles Bibliográficos
Autores principales: Warkentin, Alexander A, Lopez, Michael S, Lasater, Elisabeth A, Lin, Kimberly, He, Bai-Liang, Leung, Anskar YH, Smith, Catherine C, Shah, Neil P, Shokat, Kevan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2014
Materias:
Biochemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307180/
https://www.ncbi.nlm.nih.gov/pubmed/25531068
http://dx.doi.org/10.7554/eLife.03445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307180/
https://www.ncbi.nlm.nih.gov/pubmed/25531068
http://dx.doi.org/10.7554/eLife.03445

Ejemplares similares